NanoGroup S.A.
ISIN: PLNNGRP00011 | Ticker: NNG | LEI: 259400HXWEAZUWRLY648
Country: Poland
Mission of NanoGroup is to build a cluster of medical and biotechnological companies active in the field of diagnostics, therapy and rehabilitation of oncological patients.
Currently, the group is managing five technologically advanced nanoengineering projects organized under three specialized startups.
NanoGroup plans to sell licenses to its early-stage solutions (pre-clinical and clinical phase 1st) to international biotech companies and pharmaceutical companies.
2013
Served areaWorldwide
HeadquartersRakowiecka 36, 02-532 Warszawa – Poland
| Line item in (pln) | 02.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 20,301,901.00 | 19,198,782.00 |
| Noncurrent Assets | N/A | 15,217,633.00 | 16,269,092.00 |
| Property Plant And Equipment | N/A | 432,149.00 | 295,513.00 |
| Goodwill | N/A | 0.00 | 0.00 |
| Intangible Assets Other Than Goodwill | N/A | 14,426,466.00 | 15,785,749.00 |
| Other Noncurrent Financial Assets | N/A | 25,146.00 | 37,965.00 |
| Current Assets | N/A | 5,084,268.00 | 2,929,690.00 |
| Inventories | N/A | 48,350.00 | 46,478.00 |
| Current Trade Receivables | N/A | 523,738.00 | 57,785.00 |
| Cash and cash equivalents | 9,774,533.00 | 3,999,486.00 | 2,470,927.00 |
| Equity And Liabilities | N/A | 20,301,901.00 | 19,198,782.00 |
| Equity | 18,767,076.00 | 8,365,709.00 | 7,783,019.00 |
| Issued Capital | N/A | 16,747,883.00 | 16,747,883.00 |
| Retained Earnings | N/A | -26,232,328.00 | -30,320,012.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | -10,005,432.00 | -838,592.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | -16,226,896.00 | -29,481,420.00 |
| Share Premium | N/A | 29,350,927.00 | 29,350,927.00 |
| Reserve Of Sharebased Payments | N/A | 380,664.00 | 3,818,606.00 |
| Equity Attributable To Owners Of Parent | N/A | 7,733,812.00 | 7,084,070.00 |
| Noncontrolling Interests | N/A | 631,897.00 | 698,949.00 |
| Liabilities | N/A | 11,936,192.00 | 11,415,763.00 |
| Noncurrent Liabilities | N/A | 7,431,696.00 | 9,991,757.00 |
| Noncurrent Government Grants | N/A | 7,290,468.00 | 9,991,757.00 |
| Deferred Tax Liabilities | N/A | 2,056.00 | 0.00 |
| Current Liabilities | N/A | 4,504,496.00 | 1,424,006.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 280,222.00 | 202,674.00 |
| Current Tax Liabilities Current | N/A | 123,736.00 | 155,203.00 |
| Line item in (pln) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 492,492.00 | 139,549.00 |
| Other Income | 80,715.00 | 4,180,281.00 |
| Raw Materials And Consumables Used | 185,896.00 | 95,784.00 |
| Services Expense | 1,721,144.00 | 1,746,154.00 |
| Employee Benefits Expense | 1,625,133.00 | 2,285,236.00 |
| Depreciation And Amortisation Expense | 64,348.00 | 62,189.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 7,536,110.00 | 839,048.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 7,536,110.00 | 839,048.00 |
| Tax Expense Other Than Income Tax Expense | 26,936.00 | 76,014.00 |
| Profit Loss From Operating Activities | -10,586,360.00 | -784,595.00 |
| Finance Income | 3.00 | 2,455.00 |
| Finance Costs | 108,147.00 | 1,365.00 |
| Profit Loss Before Tax | -10,694,504.00 | -783,505.00 |
| Income Tax Expense Continuing Operations | -11,965.00 | -11,965.00 |
| Profit Loss From Continuing Operations | -10,682,539.00 | -771,540.00 |
| Profit Loss From Discontinued Operations | 0.00 | 0.00 |
| Profit (loss) | -10,682,539.00 | -771,540.00 |
| Profit Loss Attributable To Owners Of Parent | -10,005,432.00 | -838,592.00 |
| Profit Loss Attributable To Noncontrolling Interests | -677,107.00 | 67,052.00 |
| Line item in (pln) | 01.01.2022 | 02.01.2021 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | -10,682,539.00 | N/A | -771,540.00 |
| Adjustments For Reconcile Profit Loss | 8,041,082.00 | N/A | -2,901,407.00 |
| Adjustments For Decrease Increase In Inventories | -48,350.00 | N/A | 1,872.00 |
| Adjustments For Depreciation And Amortisation Expense | 64,348.00 | N/A | 62,189.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 7,512,630.00 | N/A | -3,392,371.00 |
| Adjustments For Provisions | -108,474.00 | N/A | 0.00 |
| Adjustments For Sharebased Payments | 278,772.00 | N/A | 88,366.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | 0.00 | N/A | 0.00 |
| Other Adjustments To Reconcile Profit Loss | 549,833.00 | N/A | 19,378.00 |
| Adjustments For Reconcile Profit Loss | 8,041,082.00 | N/A | -2,901,407.00 |
| Cash Flows From Used In Operations | -2,653,422.00 | N/A | -3,684,912.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 0.00 | N/A | 0.00 |
| Cash Flows From Used In Operating Activities | -2,653,422.00 | N/A | -3,684,912.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 50,044.00 | N/A | 8,412.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 3,820,806.00 | N/A | 798,456.00 |
| Cash Flows From Used In Investing Activities | -3,870,850.00 | N/A | -806,868.00 |
| Proceeds From Issuing Shares | 1,000.00 | N/A | 3,349,576.00 |
| Proceeds From Borrowings Classified As Financing Activities | 0.00 | N/A | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | 0.00 | N/A | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 0.00 | N/A | 146,146.00 |
| Proceeds From Government Grants Classified As Financing Activities | 988,184.00 | N/A | 158,767.00 |
| Interest Paid Classified As Financing Activities | 0.00 | N/A | 0.00 |
| Cash Flows From Used In Financing Activities | 749,225.00 | N/A | 2,963,221.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -5,775,047.00 | N/A | -1,528,559.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 0.00 | N/A | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -5,775,047.00 | N/A | -1,528,559.00 |
| Cash and cash equivalents | 3,999,486.00 | 9,774,533.00 | 2,470,927.00 |
Please note that some sums might not add up.
PLNNGRP00011
LEI259400HXWEAZUWRLY648
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.